A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
Public ClinicalTrials.gov record NCT02108652. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment in participants with locally advanced or metastatic urothelial bladder cancer. Participants will be enrolled into 1 of 2 cohorts. Cohort 1 will consist of participants who are treatment-naïve and ineligible for cisplatin-containing chemotherapy. The results of Cohort 1 are reported separately (NCT02951767). Cohort 2 (reported here) will contain participants who have progressed during or following a prior platinum-based chemotherapy regimen. Participants in both cohorts will be given a 1200 milligrams (mg) intravenous (IV) dose of atezolizumab on Day 1 of 21-day cycles. Treatment of participants in Cohort 1 will continue until disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or unmanageable toxicity. Treatment of participants in Cohort 2 will continue until loss of clinical benefit or unmanageable toxicity.
Study identification
- NCT ID
- NCT02108652
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 310 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2014 (Actual)
- Primary completion
- Jul 4, 2016 (Actual)
- Completion
- Feb 28, 2023 (Actual)
- Last update posted
- Mar 28, 2024
2014 – 2023
United States locations
- U.S. sites
- 47
- U.S. states
- 24
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama At Birmingham | Birmingham | Alabama | 35294 | — |
| Pinnacle Oncology Hematology | Scottsdale | Arizona | 85258 | — |
| Arizona Oncology - HOPE Wilmot | Tucson | Arizona | 85710 | — |
| UCLA | Los Angeles | California | 90024 | — |
| The Angeles Clinic and Research Institute - W LA Office | Los Angeles | California | 90025 | — |
| USC Norris Cancer Center | Los Angeles | California | 90033 | — |
| UCSF | San Francisco | California | 94143-0106 | — |
| Kaiser Permanente - San Marcos | San Marcos | California | 92069 | — |
| Stanford Cancer Center | Stanford | California | 94305-5820 | — |
| Kaiser Permanente; Oncology Clinical Trials | Vallejo | California | 94589 | — |
| Rocky Mountain Cancer Center - Aurora | Aurora | Colorado | 80012 | — |
| University Of Colorado | Aurora | Colorado | 80045 | — |
| University of Connecticut Health Center | Farmington | Connecticut | 06030 | — |
| Yale Cancer Center ; Medical Oncology | New Haven | Connecticut | 06520 | — |
| Georgetown University Medical Center Lombardi Cancer Center | Washington D.C. | District of Columbia | 20057 | — |
| Mayo Clinic Cancer Center | Jacksonville | Florida | 32224 | — |
| Piedmont Cancer Institute, PC | Atlanta | Georgia | 30318 | — |
| University of Chicago; Hematology/Oncology | Chicago | Illinois | 60637 | — |
| Ingalls Memorial Hospital | Harvey | Illinois | 60426 | — |
| Indiana University Health; Goshen Center for Cancer Care | Goshen | Indiana | 46526 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40402 | — |
| Massachusetts General Hospital;Oncology | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Inst. ; Dept. of Medical Oncology | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center, Harvard Medical School; Department of Medicine | Boston | Massachusetts | 02215 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Minnesota Oncology Minneapolis | Minneapolis | Minnesota | 55404 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| Urology Cancer Center & GU Research Network | Omaha | Nebraska | 68130 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89128 | — |
| New York Oncology Hematology, P.C. | Albany | New York | 12208 | — |
| NYU Langone Medical Center | New York | New York | 10016 | — |
| Mount Sinai School of Medicine - Tisch Cancer Institute | New York | New York | 10029 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45242 | — |
| Case Western Reserve Univ; Hem/Onc | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Willamette Valley Cancer Ctr - 520 Country Club | Eugene | Oregon | 97401-8122 | — |
| Kimmel Cancer Center Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Sarah Cannon Cancer Center - Tennessee Oncology, Pllc | Nashville | Tennessee | 37203 | — |
| Ctr for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| Texas Oncology - Houston (Gessner) | Houston | Texas | 77024 | — |
| Houston Methodist Hospital | Houston | Texas | 77030 | — |
| University of Texas Health Science Center at San Antonio | San Antonio | Texas | 78229 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates - Lake Wright Cancer Center | Norfolk | Virginia | 23502 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02108652, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 28, 2024 · Synced Sep 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02108652 live on ClinicalTrials.gov.